THE GROWTH-PATTERN AND FINAL HEIGHT OF GIRLS WITH TURNER-SYNDROME WITH AND WITHOUT HUMAN GROWTH-HORMONE TREATMENT

Citation
C. Dacouvoutetakis et al., THE GROWTH-PATTERN AND FINAL HEIGHT OF GIRLS WITH TURNER-SYNDROME WITH AND WITHOUT HUMAN GROWTH-HORMONE TREATMENT, Pediatrics, 101(4), 1998, pp. 663-668
Citations number
24
Categorie Soggetti
Pediatrics
Journal title
ISSN journal
00314005
Volume
101
Issue
4
Year of publication
1998
Pages
663 - 668
Database
ISI
SICI code
0031-4005(1998)101:4<663:TGAFHO>2.0.ZU;2-X
Abstract
Background. Shortness is the most frequent and quite disturbing charac teristic of girls with Turner syndrome (TS). Human growth hormone admi nistration (hGH) to girls with TS increases growth velocity (GV), but a favorable effect on final height (FH) has not been documented. The a im of this study was to evaluate the effect of hGH administration on t he growth pattern and FH in girls with TS. Methods. The study group wa s comprised of 123 girls with TS who were tared for in our center. Eig hty-two of these girls received hGH (mean dose, 0.78 +/- 0.12 IU/kg/we ek), given subcutaneously 5 to 7 times per week for a period of 2.2 +/ - 1.2 years (hGH group). The mean chronological age (CA) and bone age (BA) at hGH initiation were 11.5 +/- 25 years and 9.7 +/- 2.3 years, r espectively. The remaining 41 girls did not receive hGH and are design ated as the untreated control group. In both groups, gonadal steroids were given for pubertal initiation and maintenance. Results. The GV du ring the first year of hGH therapy (GV1) was higher than the year befo re hGH (6.3 cm/year vs 4.0 cm/year) and higher than the GV of the untr eated group at a similar CA (4.4 cm/year). The GVs during the second ( GV2) and third (GV3) year of hGH treatment (5.4 and 4.9 cm/year, respe ctively) were lower, but still higher in the hGH group, in comparison with the untreated group (GV2, 4.2 cm/year; GV3, 3.4 cm/year). GVI, GV 2 and GV3 were negatively related to age and to BA at hGH initiation. The FH of the 35 hGH-treated girls was not significantly different fro m the FH of the 27 untreated girls (146.1 cm vs 144.0 cm). The Delta t arget height-FH was not significantly different in the two groups. The FH standard deviation score of the hGH-treated group was positively r elated to height standard deviation score for CA at treatment initiati on (r = +0.73), maternal height (r = +0.57), target height (r = + 0.66 ), and birth weight (r = +0.54), but was unrelated to CA or BA at star t of therapy or to hGH dose. Conclusions. hGH therapy in girls with TS , in the dose and duration of treatment applied in this study, signifi cantly accelerated GV but did not significantly improve FH.